Los Angeles, London (February 04, 2014). Smokers are increasingly turning to electronic cigarettes as a means to reduce the health impacts of their addiction. But legislators around the world are far from unified in their approaches to regulating e-cigarettes. Misguided legislation based on concerns that are not backed by sound data may have unintended consequences for public health, experts say. With smoking behind almost six million premature deaths each year, a lot is at stake in the current round of regulation changes.
An article offering details and critique of current legislation, "Achieving appropriate regulations for electronic cigarettes," by communication, legal and public health experts Daniela Saitta, Giancarlo Antonio Ferro and Riccardo Polosa from the University of Catania, Italy appears in the latest Therapeutic Advances in Chronic Disease, published by SAGE.
Tar, chemicals, and other substances found in tobacco smoke cause most of the health risks from cigarettes, rather than the nicotine. E-cigarettes aim to circumvent these risks by delivering nicotine without the smoke. Yet despite users seeing the clear benefit from e-cigarettes, members of the health community, the pharmaceutical regulators and governments have voiced concerns. Fears include e-cigarettes encouraging higher nicotine consumption than traditional cigarettes, and perpetuating addiction rather than promoting quitting. The health risks from long-term e-cigarette use are as yet unknown, and e-cig detractors say that these products will appeal to young non-smokers, or make smoking publicly acceptable once again. The authors of the article argue that these claims are mostly theoretical and not backed by scientific evidence, but are often cited in moves to restrict e-cigarettes.
The authors show that efforts to address these concerns without sound data can lead to unintended consequences: the first draft of the revision of the European Union (EU) legislation proposed in December 2012 attempted to define arbitrary limits to the nicotine content in the liquid of e-cigarettes, a clear indicator of the poor understanding of the problem by legislators.. Only a few months later, the same EU health ministers proposed distinctive amendments to the first draft applying substantial pharmaceutical regulations to e-cigarettes– a move that was rejected by the EU Parliament in October 2013. This would have resulted in higher costs and limiting access (sale via pharmacies only) to consumers. The authors say:
"It is counter-productive and hypocritical to over-regulate a product designed to reduce or eliminate the diseases and early deaths caused by smoking."
Unfortunately, the UK's Medicines and Healthcare Regulatory Agency (MHRA) has moved towards regulating e-cigarettes as medical products. In Canada, electronic products that dispense nicotine by inhalation fall under the Food and Drugs Act of the Health Canada, which means it is illegal to smoke e-cigarettes, and stipulates that it must be approved as a new drug before they can be sold or imported.
Polosa and his co-authors propose that e-cigarette regulators should consider:
Moreover, regulatory frameworks for electronic products are already available in the EU legislation to cover for the safety issues regarding E-cigarettes' hardware components. . The authors note that - regrettably -such legislation may be "impossible to implement" due to the interests of the tobacco and pharmaceutical industries, and even due to revenues generated for governments by taxes on tobacco.
"If these obstacles can be overcome, much misery and suffering can be reduced and millions of lives can be saved," the authors declare.: "E-cigarettes are not a gateway to smoking but a gateway from smoking, and heavy regulation by restricting access to e-cigarettes would just encourage continuing use of much unhealthier tobacco smoking."
"Achieving appropriate regulations for electronic cigarettes," by Daniela Saitta, Giancarlo Antonio Ferro and Riccardo Polosa, published February 04 2014, appears in the journal Therapeutic Advances in Chronic Disease.
This article will be freely accessible for a limited time here.
SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology, and medicine. An independent company, SAGE has principal offices in Los Angeles, London, New Delhi, Singapore, and Washington DC. http://www.sagepublications.com.
Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases (excluding cancer). The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across areas of drug treatment of all major chronic diseases (excluding cancer, which is covered in Therapeutic Advances in Medical Oncology).
This journal is a member of the Committee on Publication Ethics (COPE). http://taj.sagepub.com/
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.